Adeno-associated virus vector-mediated gene delivery to the vasculature and kidney.
Relatively successful elsewhere, gene delivery aimed at the vasculature and kidney has made very little progress. In the kidney, the hurdles are related to the unique structure-function relationships of this organ and in the blood vessels to a variety of, mostly endothelial, factors making the delivery of transgenes very difficult. Among gene-therapeutic approaches, most viral gene delivery systems utilized to date have shown significant practical and safety-related limitations due to the level and duration of recombinant transgene expression as well as their induction of a significant host immune response to vector proteins. Recombinant adeno-associated virus (rAAV) vectors appear to offer a vehicle for safe, long-term transgene expression. rAAV-based vectors are characterized by a relative non-immunogenicity and the absence of viral coding sequences. Furthermore, they allow for establishment of long-term latency without deleterious effects on the host cell. This brief review addresses problems related to transgene-delivery to kidney and vasculature with particular attention given to rAAV vectors. The potential for gene therapy as a strategy for selected renal and vascular diseases is also discussed.
Kapturczak
Matthias H
MH
Division of Nephrology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA. kaptur@uab.edu
Chen
Sifeng
S
Agarwal
Anupam
A
D000818:Animals; D000229:Dependovirus / Q000235:genetics / Q000502:physiology*; D004730:Endothelium, Vascular / Q000378:metabolism*; D018014:Gene Transfer Techniques; D005822:Genetic Vectors / Q000235:genetics / Q000502:physiology*; D006801:Humans; D007668:Kidney / Q000378:metabolism*